159
Participants
Start Date
May 29, 2012
Primary Completion Date
November 8, 2017
Study Completion Date
February 9, 2018
Lampalizumab
Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms.
Opthalmic Consultants of LI, Lynbrook
Mid Atlantic Retina, Philadelphia
Elman Retina Group, Baltimore
Wagner Macula & Retina Center, Norfolk
Char Eye Ear &Throat Assoc, Charlotte
Western Carolina Retinal Associate PA, Asheville
Charleston Neuroscience Institute, Ladson
Southeast Retina Center, Augusta
Retina Specialty Institute, Pensacola
Florida Eye Associates, Melbourne
Retina Care Specialists, Palm Beach Gardens
Retina Group of Florida, Boca Raton
Ctr for Retina & Macular Dis, Winter Haven
National Ophthalmic Research Institute, Fort Myers
Tennessee Retina PC, Nashville
Southeastern Retina Associates, Knoxville
Retina Assoc of Cleveland Inc, Beachwood
Cincinnati Eye Institute, Cincinnati
St. Franziskus Hospital, Münster
Wolfe Eye Clinic, West Des Moines
Universitatsklinikum Bonn; Medizinische Klinik und Poliklinik III, Bonn
Medical College of Wisconsin, Milwaukee
Vitreoretinal Surgery, Edina
The Retina Institute, St Louis
Universitätsklinikum Tübingen, Tübingen
Dean McGee Eye Institute, Oklahoma City
Texas Retina Associates, Dallas
Retina Research Center, Austin
Universitätsklinikum Freiburg, Freiburg im Breisgau
W Texas Retina Consultants PA, Abilene
Colorado Retina Associates, PC, Golden
Retina Centers P.C., Tucson
Eye Associates of New Mexico, Albuquerque
Sierra Eye Associates, Reno
Retina-Vitreous Assoc Med Grp, Beverly Hills
Retina Macula Institute, Torrance
The Retina Partners, Encino
San Diego Retina Associates, Oceanside
Loma Linda University, Loma Linda
California Retina Consultants, Santa Barbara
W Coast Retina Med Group Inc, San Francisco
West Coast Retina, San Francisco
Retinal Diagnostic Center, Campbell
Retina Northwest, Portland
Ophthalmic Consultants of Boston, Boston
Universitatsklinikum Leipzig, Leipzig
Lead Sponsor
Genentech, Inc.
INDUSTRY